Activates Charcoal for Patients Undergoing Invasive Procedure Delayed Due to Direct Oral Anticoagulants
Status:
Unknown status
Trial end date:
2018-09-01
Target enrollment:
Participant gender:
Summary
This is a prospective, multicentric, randomized, open labeled superiority trial
This study aims to evaluate the efficacy of oral activated charcoal for improving elimination
of direct oral anticoagulants ( Rivaroxaban, Apixaban) in case of an unscheduled invasive
procedure delayed to this anticoagulant treatment.
The primary outcome is the anticoagulant's half life. Plasma concentration will be measured
by liquid chromatography-mass spectrometry for the main analysis (pharmacokinetic).
A total of 140 patients will randomly be assigned to the charcoal or control group,
stratified according to their anticoagulant drug.